



**HAL**  
open science

## Physical and mental health status of former smokers and non-smokers patients with bipolar disorder

Bénédicte Nobile, Ophélie Godin, Sébastien Gard, Ludovic Samalin, Georges Brousse, Joséphine Loftus, Valérie Aubin, Raoul Belzeaux, Caroline Dubertret, Yann Le Strat, et al.

### ► To cite this version:

Bénédicte Nobile, Ophélie Godin, Sébastien Gard, Ludovic Samalin, Georges Brousse, et al.. Physical and mental health status of former smokers and non-smokers patients with bipolar disorder. *Acta Psychiatrica Scandinavica*, 2023, 147 (4), pp.373-388. 10.1111/acps.13535 . inserm-04165282

**HAL Id: inserm-04165282**

**<https://inserm.hal.science/inserm-04165282>**

Submitted on 18 Jul 2023





**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

# Physical and mental health status of former smokers and non-smokers patients with bipolar disorder

**Bénédicte Nobile**<sup>1,2,3</sup>  | **Ophélie Godin**<sup>3,4</sup> | **Sébastien Gard**<sup>3,5</sup> | **Ludovic Samalin**<sup>3,6</sup> | **Georges Brousse**<sup>3,6</sup> | **Joséphine Loftus**<sup>3,7</sup> | **Valérie Aubin**<sup>3,7</sup> | **Raoul Belzeaux**<sup>1,3,8</sup> | **Caroline Dubertret**<sup>3,9</sup> | **Yann Le Strat**<sup>3,9</sup> | **Nicolas Mazer**<sup>3,9</sup> | **Alix de Prémoré**<sup>3,9</sup> | **Paul Roux**<sup>3,10</sup> | **Mircea Polosan**<sup>3,11</sup> | **Thomas Schwintzer**<sup>3,12,13,14</sup>  | **Pierre-Michel Llorca**<sup>3,6</sup> | **FondaMental Advanced Center of Expertise for Bipolar Disorders (FACE-BD) collaborators**<sup>3</sup> | **Isabelle Biseul**<sup>3,15</sup> | **Bruno Etain**<sup>3,15,16</sup>  | **Remi Moirand**<sup>3,17</sup> | **Emilie Olié**<sup>1,2,3</sup> | **Emmanuel Haffen**<sup>3,17</sup> | **Marion Leboyer**<sup>3,18</sup> | **Philippe Courtet**<sup>1,2,3</sup> | **Sébastien Guillaume**<sup>1,2,3</sup> | **Romain Icick**<sup>3,12,13,15,16</sup> 

<sup>1</sup>Department of Emergency Psychiatry and Acute Care, Lapeyronie Hospital CHU Montpellier, Montpellier, France

<sup>2</sup>Institut de Génomique Fonctionnelle, Université de Montpellier, CNRS, INSERM, Montpellier, France

<sup>3</sup>FondaMental Foundation, Créteil, France

<sup>4</sup>INSERM U955, Département Hospitalo-Universitaire de Psychiatrie et d'Addictologie des Hôpitaux Universitaires H Mondor, AP-HP, Université Paris-Est Créteil, Créteil, France

<sup>5</sup>Center Hospitalier Charles Perrens, France NutriNeuro, INRAE UMR 1286, University of Bordeaux, Pôle de Psychiatrie Générale et Universitaire, Bordeaux, France

<sup>6</sup>CHU Clermont-Ferrand, Department of Psychiatry, University of Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal, Clermont-Ferrand, France

<sup>7</sup>Center Hospitalier Princesse Grace, Pôle de Psychiatrie, Monaco, Monaco

<sup>8</sup>Pôle de Psychiatrie, Assistance Publique Hôpitaux de Marseille, INT-UMR7289, CNRS Aix-Marseille Université, Marseille, France

List of FondaMental Advanced Centre of Expertise (FACE-BD) collaborators: FACE-BD Clinical Coordinating Center (Fondation FondaMental): B. Etain, E. Olié, M. Leboyer, PM Llorca; FACE-BD Data Coordinating Center (Fondation FondaMental): V. Barteau, S. Bensalem, O. Godin, H. Laouamri, and K. Souryis; FACE-BD Clinical Sites and Principal Collaborators in France: AP-HP, DHU PePSY, Pôle de Psychiatrie et d'Addictologie des Hôpitaux Universitaires H Mondor, Créteil, France: S. Hotier, A. Pelletier, JP. Sanchez, E. Saliou, C. Hebbache, J. Petrucci, L. Willaume and E. Bourdin; APHP, Groupe Hospitalo-universitaire AP-HP Nord, DMU Neurosciences, Département de Psychiatrie et Médecine Addictologie, Hôpital Fernand Widal, Paris, France: F. Bellivier, M. Carminati, B. Etain, V. Hennion, E. Marlinge, J. Meheust, A. Richard; Hôpital C. Perrens, Centre Expert Trouble Bipolaire, Service de Psychiatrie Adulte, Pôle 3-4-7, Bordeaux, France: B. Antoniol, A. Desage, S. Gard, A. Jutant, K. Mbailara, I. Minois, and L. Zanouy; Département d'Urgence et Post Urgence Psychiatrique, CHRU Montpellier, Montpellier, France: L. Bardin, P. Courtet, B. Deffinis, D. Ducasse, M. Gachet, F. Molière, B. Noisette, E. Olié and G. Tarquini; Pôle de Psychiatrie, addictologie et pédopsychiatrie, Hôpital Sainte Marguerite, Marseille, France: R. Belzeaux, F. Groppi, E. Moreau, A. Lefrere, L. Lescalier, J. Pastol and N. Viglianese; Université de Lorraine, Centre Psychothérapique de Nancy, Inserm U1114, Nancy, France: R. Cohen, G. Gross, R. Schwan, T. Schwitzer, and O. Wajsbrot-Elgrabli; Service Universitaire de Psychiatrie, CHU de Grenoble et des Alpes, Grenoble, France: T. Bougerol, B. Fredembach, A. Suisse, A. Pouchon and M. Polosan; Centre Hospitalier de Versailles, Service Universitaire de Psychiatrie d'adultes et d'addictologie, Le Chesnay, France: A.S. Cannavo, A. Créa, V. Feuga, A.M. Galliot, N. Kayser, C. Passerieux, and P. Roux; Service de Psychiatrie, Centre Hospitalier Princesse Grace, Monaco: V. Aubin, I. Cussac, M.A Dupont, J. Loftus, I. Medecin and T. Burté; APHP, Groupe Hospitalo-universitaire AP-HP Nord, DMU ESPRIT, Service de psychiatrie et addictologie, Hôpital Louis Mourier, Colombes, France: C. Dubertret, N. Mazer, C. Portalier, C. Scognamiglio, A. Bing; Service de psychiatrie de l'adulte, CHU de Besançon: C. Aymé, D. Bennabi, E. Haffen, E. Mercelat.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2023 The Authors. *Acta Psychiatrica Scandinavica* published by John Wiley & Sons Ltd.

<sup>9</sup>INSERM UMR1266, AP-HP, Groupe Hospitalo-Universitaire AP-HP Nord, service de Psychiatrie et Addictologie, Hôpital Louis Mourier, Université de Paris, Colombes, France

<sup>10</sup>UVSQ, CESP UMR1018, DevPsy-DisAP, Centre Hospitalier de Versailles, Pôle de Psychiatrie et Santé Mentale, Université Paris-Saclay, Le Chesnay, France

<sup>11</sup>CHU de Grenoble et des Alpes, Grenoble Institut des Neurosciences (GIN) Inserm, Université Grenoble Alpes, Grenoble, France

<sup>12</sup>Centre Psychothérapique de Nancy, Pôle Hospitalo-Universitaire de Psychiatrie d'Adultes et d'Addictologie du Grand Nancy, Laxou, France

<sup>13</sup>INSERM U1254, IADI, Université de Lorraine, Nancy, France

<sup>14</sup>Faculté de Médecine, Université de Lorraine, Vandœuvre-lès-Nancy, France

<sup>15</sup>Département de Psychiatrie et de Médecine Addictologique, AP-HP-Nord, Groupe Hospitalo-universitaire Lariboisière-Fernand Widal, DMU Neurosciences, Paris, France

<sup>16</sup>INSERM UMRS 1144, Université de Paris Cité, Paris, France

<sup>17</sup>Service de Psychiatrie de l'Adulte, CIC-1431 INSERM, CHU de Besançon, Laboratoire de Neurosciences, UFC, UBFC, Besançon, France

<sup>18</sup>AP-HP, Hôpitaux Universitaires Henri Mondor, Département Médico-Universitaire de Psychiatrie et d'Addictologie (DMU IMPACT), Fédération Hospitalo-Universitaire de Médecine de Précision en Psychiatrie (FHU ADAPT), Université Paris Est Créteil, INSERM U955, Paris, France

### Correspondence

Bénédicte Nobile, IGF, Hôpital La Colombière, 39, Avenue Charles Flahault, BP 34493, 34093 Montpellier cedex 5, France.

Email: [benedicte.nobile@gmail.com](mailto:benedicte.nobile@gmail.com)

### Funding information

Fondation FondaMental; INSERM; Investissement d'Avenir Programme, Grant/Award Number: ANR-11-IDEX-0004-02 ANR-10-COHO-10-01

### Abstract

**Objectives:** Up to 70% individuals with bipolar disorder (BD) are lifetime tobacco smokers, a major modifiable risk factor for morbidity. However, quitting smoking is rarely proposed to individuals with BD, mainly because of fear of unfavorable metabolic or psychiatric changes. Evaluating the physical and mental impact of tobacco cessation is primordial. The aim of this study was to characterize the psychiatric and nonpsychiatric correlates of tobacco smoking status (never- vs. current vs. former smokers) in individuals with BD.

**Methods:** 3860 individuals with ascertained BD recruited in the network of Fondamental expert centers for BD between 2009 and 2020 were categorized into current, former, and never tobacco smokers. We compared the sociodemographic and clinical characteristics assessed by standard instruments (e.g., BD type, current symptoms load, and non-psychiatric morbidity—including anthropometric and biological data) of the three groups using multinomial regression logistic models. Corrections for multiple testing were applied.

**Results:** Current smokers had higher depression, anxiety, and impulsivity levels than former and never-smokers, and also higher risk of comorbid substance use disorders with a gradient from never to former to current smokers—suggesting shared liability. Current smokers were at higher risk to have a metabolic syndrome than never-smokers, although this was only evidenced in cases, who were not using antipsychotics.

**Conclusions:** Tobacco smoking was associated with high morbidity level. Strikingly, as in the general population, quitting smoking seemed associated with their return to the never-smokers' levels. Our findings strongly highlight the need to spread strategies to treat tobacco addiction in the BD population.

### KEYWORDS

addiction, bipolar disorder, former smokers, metabolic syndrome, tobacco

## 1 | INTRODUCTION

Bipolar disorder (BD) is a severe mental illness associated with 15–20 years of loss in life expectancy when compared with unaffected individuals.<sup>42</sup> Although BD individuals are at particularly high risk to die from unnatural causes such as suicide and accidents,<sup>37</sup> somatic comorbid disorders account for about 70% of premature death in this population,<sup>42</sup> especially because of cardiovascular and metabolic disorders (e.g., dyslipidemia, diabetes).<sup>15,54</sup> Tobacco smoking remains the main modifiable risk factor of cardiovascular and metabolic disorders in BD.<sup>10,12,21,32</sup> The lifetime prevalence of tobacco smoking is up to 70% in BD<sup>46</sup> – two to five times higher than in the general population<sup>11,26</sup> [adjusted odds = 2–5<sup>7</sup>]. Importantly regarding the adverse health effects of tobacco smoke, individuals with BD tend to smoke cigarettes more heavily and to extract more nicotine and chemicals than tobacco smokers without psychiatric disorders.<sup>46</sup>

In addition to the increased risk of developing metabolic and cardiovascular disorders, tobacco smoking may contribute to worsen the psychiatric course of BD. First, the polygenic risk for tobacco smoking has been shown to increase BD risk in two independent Mendelian randomization studies.<sup>20,55</sup> Second, there is a growing body of literature showing that tobacco smoking further increases the already high risk of suicidal behavior carried by individuals with BD,<sup>17,35</sup> especially during depressive episodes.<sup>43</sup> Fourthly, tobacco smoking is associated with a higher frequency of sleep disturbances, anger, impulsivity and emotional lability<sup>6,23,27</sup>—which can all worsen the course of BD. Moreover, tobacco smoking decreases quality of life and increases the large economic burden within patients who are likely to have already low economic income.<sup>53</sup> Finally, tobacco smoking interacts with medications prescribed in BD<sup>58</sup> by inducing the cytochrome P450 1A2, that metabolizes numerous psychotropic medications such as antidepressants<sup>49</sup> and antipsychotics.<sup>3</sup> Thus, tobacco smoking may decrease the efficiency of these treatments, as previously suggested in a randomized trial involving anti-manic medications.<sup>5</sup>

Overall, it appears crucial to treat tobacco smoking (which will be used as proxy term for tobacco addiction/tobacco use disorders in the current manuscript) in individuals with BD. Available evidence suggest that extant strategies are effective and safe in this population,<sup>2,21,26</sup> and that the motivation to quit smoking in individuals with BD is similar to that of unaffected individuals.<sup>11</sup> However, the remission rates (using “quit smoking” as a proxy for remission) are about 60% lower for individuals with BD<sup>26</sup> compared with unaffected individuals.

### Significant outcomes

- Former and never-smokers had better clinical outcomes and less often metabolic syndrome than current smokers.
- Quitting smoking seemed to improve psychiatric and non-psychiatric outcomes.
- Clinicians should encourage BD individuals to quit smoking and provide intensive treatment for tobacco addiction in BD.

### Limitations

- Patients referred to the expert centers may be more adherent to care than other individuals with BD.
- The transversal design did not allow to address the causality of the findings.

Clinicians may not view smoking cessation as a priority: an online survey showed that only 33% of individuals with BD reported that they had been advised to quit by a healthcare professional.<sup>47</sup> Overall, both patients and clinicians seem to fear that smoking cessation may increase the risk to develop metabolic disorder (induced by weight gain) and/or exacerbate anxiety and depressive symptomatology,<sup>11,32</sup> while available evidence suggest the opposite<sup>20,52</sup>—provided that proper management is applied. Overall, in BD, the subgroup of former smokers is of particular interest to develop personalized management for tobacco smoking in BD by identifying factors associated with quitting smoking and by investigating the psychiatric and non-psychiatric outcomes of quitting smoking in BD (searching for potential benefits). However, studying this subgroup requires large sample sizes and a precise assessment of tobacco smoking history. Interestingly enough, most studies to date have been studying current tobacco smoking as opposed to a mix of current + former smokers,<sup>17,44,50</sup> and fewer lifetime smoking as a mix of never + former smoking.<sup>57</sup>

To address these limitations and improve our knowledge regarding relevant tobacco smoking groups in BD and particularly address the very poorly known issue of former smoker, we analyzed data from the FACE-BD cohort, reaching more than 3000 individuals with BD. This allowed us to perform multivariable model to identify the independent risk factors for being never versus former versus current tobacco smokers in BD.

## 2 | METHODS

### 2.1 | Participant enrolment

The FACE-BD network in France consists in 12 centers from different regions in France<sup>30</sup> coordinated by Fondation FondaMental ([www.fondation-fondamental.org](http://www.fondation-fondamental.org)). The first aim of this network is to support clinicians for the management of individuals with BD and give recommendation on personalized treatment strategies, which entirely guides the data collection in a computerized medical file to be further used for research through a web application (E-bipolar©). Anonymized data are stored in a national database FACE-BD that was approved by the French body overseeing the safety of computerized databases (Commission Nationale de l'Informatique et des Libertés, DR-2011-069). Secured access to this web-based system for research purposes is regulated by a scientific committee, who evaluates each project.

Individuals with BD are referred by a general practitioner or a psychiatrist to the expert center where they are assessed and followed annually for 3 years. Practitioners refer patients along with a referral letter that includes their main request and the related medical history. Patients are referred to the expert center for two main reasons: (1) Confirm or infirm diagnosis of BD; (2) provide personalized therapeutic guidance for BD. At inclusion and follow-up visits, the same evaluation package is used in all centers. The assessment protocol was approved by the relevant ethical review board and required only a letter of information to the patients to ascertain their non-opposition to the use of their data (CPP-IIe de France IX, 18 January 2010).

### 2.2 | Clinical assessment

#### 2.2.1 | Clinical interview

Patients are first evaluated by a senior psychiatrist specialized in BD. Once the diagnosis is confirmed, a whole-day assessment is planned involving nurses, psychiatrists and psychologists from the expert center.

The type of BD [i.e., type 1, type 2 and not otherwise specified (NOS)] and the presence of current and lifetime comorbid psychiatric disorders—especially anxiety and substance use disorders (SUDs)—are ascertained using the Structured Clinical Interview for DSM-IV Axis I Disorders.<sup>19</sup> Then, sociodemographic characteristics (age, gender, education level, marital and employment status) are recorded. Clinical variables deemed to thoroughly reflect the lifetime and recent course of bipolar illness are collected: number of previous manic, hypomanic, and

depressive episodes; presence of lifetime rapid cycling (defined by any 12-months period with  $\geq 4$  or more mood episodes), history of suicide attempt including their number and the presence of violent (e.g., hanging) and/or serious (e.g., need of intensive care) attempts. Finally, current treatment regimen and medical history were also asked to the patient and cross-checked using the referral letter (see also below).

#### 2.2.2 | Assessment of current mood state

Depressive and Manic symptomatology were assessed respectively with the Montgomery and Åsberg Depression Rating Scale (MADRS)<sup>41</sup> and the Young Mania Rating Scale (YMRS)<sup>59</sup> rated by clinicians from the expert centers, respectively.

#### 2.2.3 | Assessment of key dimensions of BD

A set of validated tools were further used to assess the following key dimensions of BD:

- Anxiety was assessed using the current subscale of the State Inventory Anxiety (STAI-A),<sup>8</sup> a 20-item self-report on current anxiety symptoms. Higher scores indicate higher current anxiety.
- The Affective Lability Scale (ALS) was used to assess emotional lability. This is a 54-item scale measuring changeability among four states: depression, elation, anger and anxiety.<sup>24</sup>
- The Barratt Impulsiveness Scale (BIS) was used to evaluate impulsivity. This scale is composed of 30 items assessing three dimensions of impulsivity: attentional, motor and never-planning impulsiveness. High scores indicate higher impulsivity.<sup>4</sup>
- The Childhood Trauma Questionnaire (CTQ) was used to assess the history of childhood trauma.<sup>45</sup>
- The Functioning Assessment Short Test (FAST) was used to assess global functioning.<sup>48</sup> The FAST is an interview developed to assess the disability level in patients with BD and includes items on autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal relationships, and leisure time. Higher scores indicate worse functioning.

#### 2.2.4 | Assessment of non-psychiatric comorbidity

Since BD is strongly associated with non-psychiatric comorbidity such as cardiovascular disease, a large panel

of medical conditions are assessed during the clinical examination done in the expert center for the clinical management of patients.

The following medical conditions were assessed or measured: history of cardiovascular disorders (high blood pressure, myocardial infarction, and cardiac arrhythmia), history of metabolic disorders (type 1 and 2 diabetes, dyslipidemia), anthropometric measurements of obesity: waist circumference in centimeters (as a marker of abdominal obesity) and body mass index (BMI, in  $\text{kg}/\text{m}^2$ ). This clinical assessment is systematically completed with blood test including complete blood count, ionogram, lipid levels and fasting glucose.

In our study, the presence of a metabolic syndrome was defined according to the criteria of the National Cholesterol Education Program's Adult Treatment Panel III report (ATP III),<sup>18</sup> which requires that three or more of the following five criteria be met: hypertriglyceridemia ( $\geq 1.7$  mmol/L or use of lipid-lowering medication), high waist circumference ( $>94$  cm for men and  $>80$  cm for women), high fasting glucose concentration ( $\geq 5.6$  mmol/L or use of glucose-lowering medication), low HDL-C level ( $<1.03$  mmol/L in men and  $<1.29$  mmol/L in women) and high blood pressure ( $\geq 130/85$  mm Hg or use of antihypertensive medication). We also considered dyslipidemia as a self-reported diagnosis.

Further details regarding recruitment and assessment procedure can be found elsewhere.<sup>30–32</sup> It is important to note that patients from the FACE-BD cohort are representative of BD outpatients attending tertiary care settings, especially regarding BD characteristics (e.g., rapid cycling, number of lifetime manic episodes) and prevalence of comorbid anxiety disorders.<sup>29,39</sup> They were all referred from primary care centers, thus representing a large part of BD outpatients seen by practitioners.

Of note, given that assessments are based on DSM-IV criteria, the term “substance use disorders” will refer to lifetime abuse or dependence throughout the manuscript. To avoid working with very small subgroups, SUDs not related to alcohol nor cannabis were defined as “other SUDs” throughout the manuscript.

### 2.2.5 | Definition of current tobacco status

We defined three groups of patients, based on their current tobacco smoking status: never-smoker, current smoker, and former smoker, as follows:

- Current smoker: “smoking at least five cigarettes per day for at least three months.” This definition was chosen since it is a valid proxy to assess nicotine dependence that meets DSM-IV criteria.<sup>32</sup>

- Former smoker: “smoked more than 100 cigarettes over the lifespan, but none over the past year.”<sup>32</sup>
- Never-smoker: “smoked less than 100 cigarettes over the lifespan.”

Users of other forms of non-medical nicotine than cigarettes were classified as non/never-smokers and very light smokers were also most often classified as non/never-smokers.

## 2.3 | Statistical analysis

Categorical variables are presented as counts (percentages), and quantitative variables as means with standard deviation (SD) or medians with interquartile ranges (IQR). Univariate multinomial logistic regression models were used to assess the association between independent variables (socio-demographic and clinical variables) and smoking status. The never-smoker group was defined as the reference group. For comparison between current versus former smoker the current smoker group was chosen as reference except when comparing SUD and current treatment (to have the OR in the right direction). The adjusted odds ratios (OR) and 95% confidence intervals (CI) were also calculated to estimate the risk associated with smoking status and sociodemographic and clinical variables.

Finally, a multivariate multinomial logistic regression model was performed including all independent variables associated with smoking status with a  $p$ -value  $<0.1$ . The adjusted odds ratios (OR) and 95% confidence intervals (CI) were also estimated. Variables that were highly correlated or collinear, defined as variance inflation factor (VIF)  $>2.5$ , were excluded from the multivariate models (e.g., anxiety and depression levels were highly correlated thus we only kept depression level in the final model).

The significance level was set at  $p$ -value  $<0.05$  for all global  $p$ -value. This was a post-hoc analysis of a cohort previously used for analysis, thus, we applied post-hoc corrections using two methods: significant  $p$ -values across the three smokers' groups were corrected using the Benjamini–Hochberg False Discovery Rate (FDR) and pairwise comparisons were corrected by the Bonferroni method, yielding  $p < 0.05/3 = 0.016$  for significance. Analyses were performed using the SPSS software (version 26.0.0.0; IBM SPSS Statistics for Windows. Armonk, NY: IBM Corp) and R software.

## 3 | RESULTS

Data regarding smoking status was available for 3625 (93.9% of all data extracted from the database) patients. There were 1529 (42.2%) never-smokers, 1680 (46.3%) current smokers

and 416 (11.5%) former smokers. The mean age of the sample was 40.6 (SD = 12.9) years and 61.6% were women. Regarding BD type, 45.7% were BD-1, 43.5% BD-2 and 10.8% BD-NOS, with a mean disorder duration of 16.8 (SD = 11.2) years. As previously published, participants from the FAC-BD cohort are mostly euthymic,<sup>31</sup> but often also show residual depressive symptoms, as shown by a mean MADRS = 10.6 (SD = 9.2) and median YMRS = 1 (IQR = 0–3).

### 3.1 | Sociodemographic characteristics according to smoking status

As compared with never-smokers, current smokers were significantly more likely to be men ( $p = 0.008$ ). Current and former smokers were less likely to be currently employed than never-smokers group. Former smokers were older than both never- and current smokers (OR = 1.02, 95% CI = [1.01; 1.03],  $p < 0.001$ ; OR = 1.05, 95% CI = [1.04; 1.06],  $p < 0.001$ , respectively), while current smokers were younger than never-smokers (OR = 0.97, 95% CI = [0.97; 0.98],  $p < 0.001$ ). Both former and never-smokers were more often in a relationship than current smokers (both  $p < 0.001$ ; Table 1A).

### 3.2 | Course and symptoms load of BD according to smoking status

BD-1 was preferentially associated with current smoking as compared with never-smokers ( $p = 0.006$ ) and showed younger age at BD onset than both never- and former smokers (both  $p < 0.001$ ), while there was no difference between the latter groups. Both current and never-smokers reported higher number of depressive episodes by duration of BD than former smokers. Current smokers had significantly higher risk of lifetime suicide attempt than both never- (OR = 1.5, 95% CI = [1.3; 1.7],  $p$ -value  $< 0.001$ ) and former smokers (OR = 1.4, 95% CI = 1.1;1.7,  $p$ -value = 0.04) but the difference was not significant between former and never-smokers (Table 1B).

Current smokers also had significantly higher scores of depression (MADRS), anxiety (STAI-A) and emotional lability (ALS) than never-smokers, while there were no differences with former smokers nor between former and never-smokers. Mean impulsivity showed an increasing gradient from never- to former to current smokers (all pairwise  $p$  significant). Former and current smokers both reported higher CTQ total score than never-smokers ( $p = 0.006$  and  $p = 0.004$ , respectively). Finally, current smokers reported significantly worse functioning than both never- and former smokers (OR = 1.02, 95% CI = [1.01; 1.02],  $p < 0.001$ ; OR = 0.99, 95% CI = [0.98;

0.99],  $p = 0.001$ , respectively) while there were no differences between former and never-smokers.

### 3.3 | Comorbid SUDs as according to tobacco smoking status

There was a gradient toward increasing prevalence of each comorbid SUD from never- to current smokers, with odds ratios ranging from 2.5 (other SUDs, former vs. never-smokers) to 3.3 (other SUDs, current vs. never-smokers). All pairwise tests were significant (Table 1C), except regarding other SUDs between current and former smokers.

### 3.4 | Non-psychiatric disorders according to smoking status

Former smokers showed a poorer metabolic profile compared with both never and current smokers, with significantly higher BMI and waist circumference and significantly more frequent dyslipidemia and metabolic syndrome. There were different patterns of associations with high blood pressure and cardiac arrhythmia, which were both significantly more frequent in never- and former smokers compared with current smokers ( $p < 0.001$  and  $p = 0.005$ , respectively). Never smokers had significantly higher risk to report type 2 diabetes than current smokers (OR = 2, 95% CI = 1.2–3.4,  $p = 0.04$ ) but there was no difference between former smokers and both never- and current smokers. Finally, there was no significant difference between tobacco smokers' groups regarding C-reactive protein, asthma, dysthyroidism, epilepsy and neoplasia (Table 1D).

### 3.5 | Current psychotropic medications

Neuroleptics and atypical antipsychotics were more frequently prescribed to current smokers than to the two other smokers groups (Table 1E). Those medications were pooled for further analysis. No other medication type was associated with smoking status.

### 3.6 | Multivariate analysis

When the significant variables from bivariate analyses were analyzed in a multivariate model (Table 2), the strongest factors associated with smoking status were age at interview (younger age of current smokers vs. the two other groups and older age of former vs. never-smokers,  $p < 0.001$  for all) and lifetime comorbid alcohol use

TABLE 1 Association between smoking status and sociodemographic and clinical data

<b>(A) Sociodemographic characteristics according to smoking status</b>									
Variable	Former smoker		Current smoker 1680 (46.3%)	Former vs. never-smoker		Current vs. former smoker		Current vs. never-smoker	
	Never smoker 1529 (42.2%)	416 (11.5%)		Odds ratio [95% CI]	p-Value	Odds ratio [95% CI]	p-Value	Odds ratio [95% CI]	p-Value
Men (vs. women)	535 (35)	174 (41.9)	681 (40.5)	0.003	1.34 [1.07; 1.67]	0.08	0.99	1.27 [1.1; 1.46]	0.008
Age (years)	42.2 (13.6)	45.5 (12.5)	37.9 (11.7)	<0.001	1.02 [1.01; 1.03]	<0.001	0.95 [0.94; 0.96]	0.97 [0.97; 0.98]	<0.001
Marital status (single vs. in a relationship)	580 (44.6)	142 (39.8)	588 (42)	<0.001	0.82 [0.65; 1.04]	0.46	0.48 [0.38; 0.61]	1.71 [1.47; 1.99]	<0.001
Educational level				0.12		0.24	0.02		0.21
Primary school	303 (23.7)	93 (26.5)	328 (23.7)		1.18 [0.9; 1.56]		1.05 [0.8; 1.39]	1.12 [0.94; 1.35]	
High school	158 (12.3)	45 (12.8)	265 (19.2)		1.1 [0.76; 1.58]		0.63 [0.44; 0.89]	1.74 [1.4; 2.17]	
University	820 (64)	213 (60.7)	790 (57.1)		Ref.		Ref.	Ref.	
Currently unemployed	502 (39.2)	170 (48.3)	604 (43.9)	0.005	1.45 [1.14; 1.84]	0.03	1.19 [0.94; 1.51]	1.22 [1.04; 1.42]	0.06
<b>(B) Course and symptoms load of BD according to smoking status</b>									
BD type	Never-smoker		Current smoker 1680 (46.3%)	Former vs. never-smoker		Current vs. former smoker		Current vs. never-smoker	
	1529 (42.2%)	416 (11.5%)		Odds ratio [95% CI]	p-Value	Odds ratio [95% CI]	p-Value	Odds ratio [95% CI]	p-Value
2	712 (46.6)	186 (44.7)	678 (40.4)	<0.001	Ref.	0.23	0.94	Ref.	<0.001
1	633 (41.4)	192 (46.2)	832 (49.5)		1.16 [0.92; 1.46]		1.19 [0.95; 1.49]	1.38 [1.19; 1.6]	
NOS	184 (12)	38 (9.1)	170 (10.1)		0.79 [0.54; 1.16]		1.22 [0.84; 1.82]	0.97 [0.77; 1.23]	
Rapid cycling	227 (17.9)	53 (15.7)	225 (16.3)	0.45					
Age at onset of BD (years)	24.9 (10.4)	25.1 (10.4)	22.5 (8.4)	<0.001	1.00 [0.99; 1.01]	1	0.97 [0.96; 0.98]	0.97 [0.97; 0.98]	<0.001
Disease duration (years)	17.3 (11.9)	20.6 (11.8)	15.3 (10)	<0.001	1.02 [1.01; 1.03]	<0.001	0.96 [0.95; 0.97]	0.98 [0.98; 0.99]	<0.001

(Continues)



TABLE 1 (Continued)

(B) Course and symptoms load of BD according to smoking status										
	Never-smoker 1529 (42.2%)	Former smoker 416 (11.5%)	Current smoker 1680 (46.3%)	Global p-value	Former vs. never-smoker		Current vs. former smoker		Current vs. never-smoker	
					Odds ratio [95% CI]	p-Value	Odds ratio [95% CI]	p-Value	Odds ratio [95% CI]	p-Value
N (%) or mean (SD)										
Number of (hypo) manic episodes/BD duration	0.4 (0.6)	0.3 (0.3)	0.4 (0.4)	0.08						
Number of depressive episodes/BD duration	0.5 (0.8)	0.3 (0.3)	0.5 (0.4)	<0.001	0.36 [0.23; 0.56]	<0.001	3.23 [2.56; 5.26]	<0.001	0.99 [0.88; 1.13]	0.98
Lifetime SA	505 (34.7)	143 (35.9)	692 (43.5)	<0.001	1.06 [0.84; 1.33]	1	1.37 [1.09; 1.73]	0.04	1.45 [1.25; 1.68]	<0.001
Lifetime violent and/or serious SA	197 (40.2)	64 (45.7)	294 (44.3)	0.29						
MADRS score	10.1 (9.1)	10.1 (8.6)	11.2 (9.2)	0.003	1.00 [0.99; 1.01]	1	1.01 [1; 1.03]	0.18	1.01 [1.01; 1.02]	0.005
YMRS score (median, IQR)	2.4 (3.7)	2.4 (4)	2.4 (3.7)	0.98						
STAI-A score	41.9 (15.2)	42.9 (14.7)	44.2 (14.7)	<0.001	1.00 [0.99; 1.01]	0.67	1.01 [1; 1.01]	0.44	1.01 [1.01; 1.02]	<0.001
ALS score	1.2 (0.7)	1.3 (0.7)	1.3 (0.7)	<0.001	1.18 [0.99; 1.39]	0.30	1.17 [0.99; 1.38]	0.27	1.38 [1.24; 1.53]	<0.001
BIS score	65.2 (11.1)	67.8 (11.3)	69.3 (11.4)	<0.001	1.02 [1.01; 1.03]	0.002	1.01 [1; 1.02]	0.09	1.03 [1.03; 1.04]	<0.001
CTQ total score	41.9 (14.4)	44.8 (15.6)	43.8 (14.7)	<0.001	1.01 [1.01; 1.02]	0.006	1 [0.99; 1.01]	0.52	1.01 [1.00; 1.01]	0.004
FAST total score	19.9 (14.5)	20.4 (14.6)	23 (14.8)	<0.001	1 [0.99; 1.01]	1	1 [1; 1.02]	0.01	1.02 [1.01; 1.02]	<0.001
(C) Comorbid SUDs as a function of tobacco smoking status										
	Never-smoker 1529 (42.2%)	Former smoker 416 (11.5%)	Current smoker 1680 (46.3%)	Global p-value	Former vs. never-smoker		Current vs. former-smoker		Current vs. never-smoker	
					OR [95% CI]	p-Value	OR [95% CI]	p-Value	OR [95% CI]	p-Value
N (%) or mean (SD)										
Alcohol use disorder	172 (12.7)	110 (28.5)	552 (37.4)	<0.001	2.74 [2.09; 3.6]	<0.001	1.5 [1.18; 1.92]	0.003	4.12 [3.4; 4.99]	<0.001
Cannabis use disorder	64 (4.7)	72 (18.7)	507 (34.4)	<0.001	4.63 [3.23; 6.63]	<0.001	2.28 [1.74; 3.03]	<0.001	10.6 [8.05; 13.9]	<0.001

TABLE 1 (Continued)

(C) Comorbid SUDs as a function of tobacco smoking status									
N (%) or mean (SD)	Never-smoker	Former smoker	Current smoker	Former vs. never-smoker		Current vs. former-smoker		Current vs. never-smoker	
	1529 (42.2%)	416 (11.5%)	1680 (46.3%)	OR [95% CI]	p-Value	OR [95% CI]	p-Value	OR [95% CI]	p-Value
Global p-value				OR [95% CI]	p-Value	OR [95% CI]	p-Value	OR [95% CI]	p-Value
Sedative use disorder	44 (3.2)	25 (6.5)	81 (5.5)	2.07 [1.25; 3.42]	<b>0.005</b>	1.19 [0.75; 1.89]	0.46	1.73 [1.19; 2.52]	<b>0.004</b>
Other substance use disorder	37 (2.7)	33 (8.5)	186 (12.6)	3.33 [2.05; 5.41]	< <b>0.001</b>	1.54 [1.05; 2.28]	<b>0.03</b>	5.14 [3.59; 7.38]	< <b>0.001</b>
(D) Non-psychiatric conditions according to smoking status									
N (%) or mean (SD)	Never-smoker	Former smoker	Current smoker	Former vs. never-smoker		Current vs. former smoker		Current vs. never-smoker	
	1529 (42.2%)	416 (11.5%)	1680 (46.3%)	OR [95% CI]	p-Value	OR [95% CI]	p-Value	OR [95% CI]	p-Value
Global p-value				OR [95% CI]	p-Value	OR [95% CI]	p-Value	OR [95% CI]	p-Value
BMI (kg/m <sup>2</sup> )	25.9 (5.5)	26.7 (5.6)	25.6 (5.2)	1.03 [1.01; 1.05]	0.08	0.96 [0.94; 0.98]	<b>0.002</b>	0.99 [0.98; 1]	0.24
Waist circumference	91.6 (14.9)	95.5 (16)	91.2 (15.6)	1.02 [1.01; 1.02]	< <b>0.001</b>	0.98 [0.98; 0.99]	< <b>0.001</b>	0.99 [0.99; 1]	0.44
Dyslipidemia	200 (14.3)	76 (19.7)	232 (15.4)	1.47 [1.1; 1.97]	0.08	0.74 [0.56; 0.99]	0.21	1.09 [0.89; 1.34]	0.79
Metabolic syndrome	258 (19.8)	100 (27)	333 (23.8)	1.5 [1.15; 1.96]	<b>0.04</b>	0.84 [0.65; 1.1]	0.52	1.27 [1.05; 1.52]	0.06
High blood pressure	120 (8.6)	56 (14.4)	68 (4.5)	1.79 [1.28; 2.52]	<b>0.002</b>	0.28 [0.19; 0.41]	< <b>0.001</b>	0.5 [0.37; 0.68]	< <b>0.001</b>
C-reactive protein (mg/L)	3.0 (4.5)	3.2 (5.8)	3.8 (7.7)	1.01 [0.98; 1.04]	0.62	1.02 [0.99; 1.05]	0.25	1.03 [1.01; 1.05]	0.01
Cardiac arrhythmia	56 (4)	20 (5.1)	34 (2.2)	1.29 [0.77; 2.18]	0.72	0.42 [0.24; 0.76]	<b>0.04</b>	0.55 [0.36; 0.85]	<b>0.04</b>
Type 2 diabetes	42 (3)	12 (3.1)	23 (1.5)	1.03 [0.51; 1.92]	1	0.49 [0.24; 0.99]	0.28	0.5 [0.29; 0.82]	<b>0.04</b>
Dysthyroidism	172 (12.4)	57 (14.5)	169 (11.1)						
Asthma	116 (8.1)	31 (7.8)	141 (9.1)						
Epilepsy	25 (1.8)	4 (1)	33 (2.2)						
Neoplasia	47 (3.5)	18 (4.7)	41 (2.8)						

(Continues)

TABLE 1 (Continued)

(E) Psychotropic medicines according to smoking status									
	Never-smoker 1529 (42.2%)	Former smoker 416 (11.5%)	Current smoker 1680 (46.3%)	Former vs. never-smoker		Current vs. former smoker		Current vs. never-smoker	
				OR [95% CI]	p-Value	OR [95% CI]	p-Value	OR [95% CI]	p-Value
	<b>N (%) or mean (SD)</b>			<b>Global p-value</b>					
Antidepressant	679 (88)	194 (88.2)	721 (89.2)	0.71					
Antipsychotic	483 (64.3)	139 (63.8)	579 (72.9)	<b>&lt;0.001</b>	0.98 [0.71; 1.34]	1.53 [1.11; 2.1]	<b>0.009</b>	1.49 [1.2; 1.86]	<b>&lt;0.001</b>
Neuroleptic	205 (29.1)	56 (28.9)	258 (35.7)	<b>0.02</b>	0.99 [0.7; 1.41]	1.37 [0.97; 1.94]	0.07	1.36 [1.09; 1.69]	<b>0.007</b>
Anxio/hypnotic	526 (76.1)	150 (78.1)	553 (78.2)	0.62					
Lithium				0.1					
No	433 (56.5)	105 (48.2)	436 (54.6)						
Yes	334 (43.5)	113 (51.8)	363 (45.4)						
Mood stabilizer	568 (73)	615 (75.8)	152 (70)	0.17					

Note: Other substance use disorder: cocaine, psychostimulant, psychedelics, opiates, others.

Abbreviations: ALS, Affective Liability Scale; BD, bipolar disorder; BIS, Barratt Impulsiveness Scale; CTQ, Childhood Trauma Questionnaire; FAST, Functioning Assessment Short Test; MADRS, Montgomery and Åsberg Depression Rating Scale; NOS, not otherwise specified; SA, suicide attempt; STAI-A, State Inventory Anxiety; YMRS, Young Mania Rating Scale. Bold values represent significant results.

TABLE 2 Multivariate analysis of factors associated with tobacco status

	Global <i>p</i> -value	Former vs. never-smoker OR [95% CI]	Current vs. former smoker <i>p</i>	Current vs. never-smoker OR [95% CI]	<i>p</i>	OR [95% CI]	<i>p</i>
Gender	0.61						
Age	<0.001	1.03 [1.01; 1.04]	<0.001	1.05 [1.03; 1.06]	<0.001	0.98 [0.97; 0.99]	<0.001
Marital status							
In a relationship vs. single	<b>0.006</b>	0.85 [0.63; 1.14]	0.28	0.63 [0.47; 0.85]	<b>0.003</b>	1.30 [1.05; 1.6]	<b>0.02</b>
Currently unemployed	<b>0.05</b>	1.29 [0.95; 1.76]	0.11	1.01 [0.73; 1.4]	0.94	1.30 [1.04; 1.63]	<b>0.02</b>
BD type	<b>0.001</b>		0.17		0.51		<0.001
2		1		1		1	
1		1.23 [0.91; 1.66]		0.84 [0.5; 1.42]		1.50 [1.2; 1.86]	
NOS		0.73 [0.44; 1.20]		0.82 [0.6; 1.11]		0.88 [0.62; 1.24]	
Alcohol use disorder	<0.001	1.83 [1.26; 2.68]	<b>0.002</b>	1.64 [1.16; 2.31]	<b>0.005</b>	2.96 [2.25; 3.89]	<0.001
Cannabis use disorder	<0.001	4.08 [2.51; 6.62]	<0.001	1.54 [1.04; 2.3]	<b>0.03</b>	6.33 [4.42; 9.05]	<0.001
Other substance use disorder	0.14						
MADRS	0.87						
ALS	0.58						
BIS	0.16						
CTQ	0.12						
FAST	0.14						
Metabolic syndrome	<b>0.03</b>	1.29 [0.92; 1.79]	0.14	1.08 [0.77; 1.51]	0.67	1.4 [1.09; 1.80]	<b>0.01</b>

Note: Other substance use disorder: cocaine, psychostimulant, psychedelics, opiates, sedative, others. Bold values represent significant results.

disorder and cannabis use disorder (higher risk for current vs never- and former smokers and for former vs. never-smokers, with ORs ranging from 1.5 to 6.3). “Other SUDs” was no more significantly associated with smoking status. There were also strong, independent associations of smoking status with BD type showing higher rates of BD of type 1 among current versus never-smokers (OR = 1.5, 95% CI = 1.2–1.9,  $p < 0.001$ ), and with marital status; current smokers being more often single than former smokers. Finally, the association between smoking status and metabolic syndrome was lost when adding neuroleptics and/or atypical antipsychotics use in the model (results not shown). To better understand the association between atypical antipsychotics/neuroleptics use, smoking status and metabolic syndrome, we performed additional analyses showing that: (i) both former and current smoking remained significantly associated with the presence of a metabolic syndrome in BD cases without antipsychotic/neuroleptic,

compared with never smokers (18% in never-smokers vs. 27% in former- and 23% in current,  $p$  corrected = 0.019 and  $p$  corrected = 0.009, respectively), but not in individuals with atypical antipsychotics/neuroleptics (overall  $p = 0.299$ )—see Figure 1; and (ii) the association between smoking status and metabolic syndrome remained after adjustment for age, gender and antipsychotic/neuroleptic only for former- versus never smokers (OR = 1.6, 95% CI = 1.3–1.9,  $p < 0.001$ ).

Table 3 further summarizes the patterns of associations with former or current smoking or both (i.e., “lifetime smoking”).

## 4 | DISCUSSION

Previous studies on the FACE-BD cohort and SUDs focused on other SUDs (e.g., alcohol use disorders<sup>33</sup>) or on the presence of any SUD and specific characteristics




FIGURE 1 Association between smoking status, antipsychotics intake and metabolic syndrome

TABLE 3 Summary of findings showing associations with current, former, and/or lifetime tobacco smoking

	Preferential associations with former tobacco smoking	Preferential associations with current tobacco smoking	Associations with any lifetime tobacco smoking
Age	Increased	Decreased	Both directions
Marital status		Being single	
BD type		BD type 1 more frequent	
Lifetime SA			
Alcohol use disorder			Increasing prevalence from never to current smoking
CTQ	Higher score vs. current smokers		
Metabolic syndrome			Higher prevalence (may be linked to lifestyle and antipsychotic treatment)

Note: Bold values represent significant results.

of BD (e.g., suicidal behavior).<sup>34,35</sup> In the current study, we focused specifically on lifetime tobacco smoking status, analyzing separately former smokers from the two other groups and its association with the characteristics of BD. In addition, we aimed at extending our previous findings regarding the characteristics of current versus former versus never smokers with BD, since evidence remained scarce in our previous study, where the group of former smokers was relatively small ( $N = 78$ ) and multivariate analysis was not deemed relevant.<sup>32</sup> Accordingly, in this new study, we were able to investigate associations with a large range of clinical characteristics, metabolic and biological variables, and current smoking status. We first confirmed an alarming rate of about 58% lifetime smoking in BD, noticing that only 19.8% of them

had quit smoking, that is, half of the rates found in the general population.<sup>38</sup> After adjusting for multiple confounders, we evidenced preferential associations with either current or former tobacco smoking, as follows: BD type 1, being single, and fulfilling the criteria for metabolic syndrome and current smoking; and higher scores for childhood trauma with former smoking (Table 3). Additionally, there was an increasing gradient from never- to former to current tobacco smokers regarding the risk of comorbid SUDs. Our findings initially suggested that both the use of antipsychotic and the metabolic syndrome were associated with smoking status, but that these associations were lost in the fully adjusted model, supporting the existence of complex relationships between these three variables.

Tobacco smoking has been consistently associated with other SUDs in BD<sup>14</sup> and in the general population.<sup>13</sup> This supports the hypothesis that nicotine exposure may increase the risk of associated SUDs,<sup>16,25</sup> but also that all SUDs may share genetic vulnerability—at least to some extent.<sup>1</sup> Additionally, one can also hypothesize that the likelihood of successfully quitting tobacco smoking is reduced by the presence of comorbid SUDs, whether it is because of the general profile of these patients (including impulsiveness and/or childhood trauma) or to the negative impact of SUDs on treatment-seeking and adherence.

The large sample size also allowed us to re-examine the relationships between tobacco smoking status and psychological/psychiatric outcomes, namely: suicide attempts, emotional lability, impulsivity, current mood symptoms and functioning—all being key issues in BD. Although examining trait characteristics may be considered relevant for lifetime conditions only (e.g., lifetime smoking), we kept our three smoking groups for all analyses in order to detect traits associated with the likelihood of smoking cessation. No trait characteristic remained associated with tobacco smoking status after multiple adjustment, as was previously evidenced regarding impulsivity.<sup>27</sup> However, although individuals were globally euthymic, current smokers had significantly higher scores for depression, anxiety, and emotional lability. They also had higher rates of suicide attempts and poorer global functioning than never- and former smokers. These findings suggest that, regarding psychiatric outcomes in BD, patients who quit tobacco smoking may show better outcomes regarding anxiety, depression and functioning than current smokers. However, these associations did not remain significant in multivariate analyses.

Regarding non-psychiatric comorbidities, former smokers had an overall less favorable metabolic profile than current smokers regarding weight, blood pressure, and dyslipidemia. Some of these findings could be explained by the appetite suppressant effect of tobacco consumption,<sup>9,22,40</sup> or by the fact that individuals with BD, who smoke tobacco, are not commonly using smoking cessation strategies, which are known to help reducing increase of appetite. Furthermore, impulsivity being higher for lifetime (current or former) versus never-smokers, one can hypothesize that these patients have maladaptive eating behaviors that increased their risk of metabolic syndrome. Eventually, despite bivariate analyses showing associations between lifetime smoking and increased risk of metabolic syndrome, this was no more the case when other variables—including age and anti-psychotics use—were considered. This is of utmost relevance for clinicians and patients, who may fear weight gain and blood pressure changes associated with smoking cessation. Our findings regarding metabolic syndrome

suggest that smoking cessation can be expected to have a very limited negative impact—if any—on the most significant components of metabolic health, despite possible increase in weight. This is all the most interesting since former smokers were older in our sample than current smokers and that metabolic syndrome is often associated with older age, reinforcing a probable “no greater negative effect” of smoking cessation on metabolic status. This is particularly similar to additional study of individuals suffering from either schizophrenia or BD in a trial of varenicline for smoking cessation, where tobacco quitters showed increases in weight and blood pressure, but decreases in cardiovascular risk.<sup>2</sup>

Our study has several limitations. First, the transversal design did not allow us to address the causality of our findings. We did not measure the duration and amount of exposure to tobacco, nor assessed tobacco use disorders using DSM criteria, which could have yielded different associations than those we evidenced. Further, the method used to quit smoking (e.g., with or without proper treatment) was not assessed and could increase heterogeneity of the former smoker group. Indeed, individuals who quit smoking without support may have worse clinical outcomes than the others may. In addition, both lifetime smokers groups showed higher risk of comorbid SUDs, noticing that the concurrent use of multiples substances is very likely to influence clinical characteristics, which may explain why some associations did not withstand multiple adjustments. Even if we performed a multivariate analysis adjusted on the different comorbid SUDs, the effect of multiple substance use cannot be totally ruled out. Finally, patients referred to the expert centers are followed regularly by a practitioner and volunteer to be assessed, which suggests that they have high levels of adherence to care and possibly lower clinical instability than other clinical samples with BD. With that regard, patients from the FACE-BD have been shown to present residual symptoms, including chronic perturbations, that have a major impact on levels of functioning.<sup>29</sup> Overall, this suggests that the FACE-BD cohort is representative of tertiary care samples with BD, somewhere between the general population and acute ward samples.

Our group and others have hypothesized that the course of bipolar illness could be improved by properly managed smoking cessation. The current findings support this view, although based on retrospective data only. BD (and probably psychiatric disorders in general) remains a risk factor for persistent smoking compared with unaffected individuals.<sup>56</sup> Tobacco smoking has been associated with a wide range of psychiatric/psychological and non-psychiatric difficulties in BD<sup>25,38,44</sup> and it decreases the plasma levels and the effectiveness of several psychotropic drugs.<sup>5</sup> Finally, smoking also impacts

quality of life of patients with BD.<sup>53</sup> For these reasons, among others, smoking cessation should be a priority. Yet, in real clinical practice smoking cessation within patients remains difficult and not often encouraged for different reasons.<sup>36</sup> Clinicians and patients may fear to worsen the psychiatric disorder or the metabolic status (including weight gain),<sup>11</sup> patients with more severe BD may be more reluctant to quit than others due to, for example, reduced feeling of self-efficacy and BD patients tend to be heavier smokers than unaffected individuals.<sup>46</sup> Treating tobacco addiction in BD may thus require particular and intensive strategies. Such strategies have been evidenced to be acceptable and efficient,<sup>28</sup> especially during teachable moments such as cancer treatment.<sup>51</sup>

In conclusion, prospective studies are necessary to confirm our results and to assess causality of our findings (e.g., metabolic syndrome and smoking status). Nevertheless, this study stresses the necessity to encourage smoking cessation for BD individuals, especially since recent randomized controlled trials demonstrated efficacy and security of therapies for smoking cessation in these patients.<sup>2,21,26</sup> Our findings suggest that quitting smoking may be more difficult for the most severe patients, but that patients with BD as a group are expected to benefit from quitting regarding their psychiatric and metabolic health. As proposed by scholarly associations such as the RANZCP, smoking cessation should be systematically proposed to people suffering from BD.

## ACKNOWLEDGMENTS

The authors thank the FondaMental Foundation ([www.fondation-fondamental.org](http://www.fondation-fondamental.org)), private foundation supporting research in mental health that is developing a new model of translational research in psychiatry in France and supports the infrastructure of Bipolar Expert Centers. We express all our thanks to the nurses, and to the patients who were included in the present study. We thank Hakim Laouamri, and his team (Seif Ben Salem, Stephane Beaufort, Karmène Souyris, Victor Barteau and Mohamed Laaidi) for the development of the FACE-BD computer interface, data management, quality control, and regulatory aspects.

## FUNDING INFORMATION

This work was funded by Fondation FondaMental (RTRS Santé Mentale), by the Investissements d'Avenir program managed by the ANR under reference ANR-11-IDEX-0004-02 and ANR-10-COHO-10-01, and by INSERM (Institut National de la Santé et de la Recherche Médicale).

## CONFLICT OF INTEREST STATEMENT

The authors declare no conflicts of interest.

## PEER REVIEW


The peer review history for this article is available at <https://publons.com/publon/10.1111/acps.13535>.

## DATA AVAILABILITY STATEMENT

Due to ethical and legal restrictions, data involving clinical participants cannot be made publicly available. All relevant data are available upon request to the Fondation FondaMental for researchers who meet the criteria for access to confidential data.

## ORCID

Bénédicte Nobile  <https://orcid.org/0000-0002-2570-6996>

Thomas Schwintzer  <https://orcid.org/0000-0001-5089-248X>

Bruno Etain  <https://orcid.org/0000-0002-5377-1488>

Romain Icick  <https://orcid.org/0000-0002-5078-4048>

## REFERENCES

- 23 and Me Research Team, Walters RK, Polimanti R, et al. Transancestral GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric disorders. *Nat Neurosci*. 2018;21:1656-1669. doi:10.1038/s41593-018-0275-1
- Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. *Lancet*. 2016;387:2507-2520. doi:10.1016/S0140-6736(16)30272-0
- Augustin M, Schoretsanitis G, Pfeifer P, Gründer G, Liebe C, Paulzen M. Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations. *Schizophr Res*. 2019;210:143-148. doi:10.1016/j.schres.2019.05.033
- Baylé FJ, Bourdel MC, Caci H, et al. Structure factorielle de la traduction française de l'échelle d'impulsivité de Barratt (BIS-10). *Can J Psychiatry*. 2000;45:156-165. doi:10.1177/070674370004500206
- Berk M, Ng F, Wang WV, et al. Going up in smoke: tobacco smoking is associated with worse treatment outcomes in mania. *J Affect Disord*. 2008;110:126-134. doi:10.1016/j.jad.2008.01.018
- Bisol LW, Soldado F, Albuquerque C, Lorenzi TM, Lara DR. Emotional and affective temperaments and cigarette smoking in a large sample. *J Affect Disord*. 2010;127:89-95. doi:10.1016/j.jad.2010.04.016
- Blanco C, Compton WM, Saha TD, et al. Epidemiology of DSM-5 bipolar I disorder: results from the National Epidemiologic Survey on alcohol and related conditions – III. *J Psychiatr Res*. 2017;84:310-317. doi:10.1016/j.jpsychires.2016.10.003
- Borteyrou X, Bruchon-Schweitzer M, Spielberger CD. The French adaptation of the STAXI-2, C.D. Spielberger's state-trait anger expression inventory. *Encephale*. 2008;34:249-255. doi:10.1016/j.encep.2007.06.001
- Bunney PE, Hansen M, LeSage M. Effects of isolated tobacco alkaloids and tobacco products on deprivation-induced food intake and meal patterns in rats. *Pharmacol Biochem Behav*. 2018;165:45-55. doi:10.1016/j.pbb.2017.11.004

10. Carlsson S, Kuja-Halkola R, Magnusson C, Lagerros YT, Andersson T. Tobacco and type 2 diabetes: is the association explained by genetic factors? *Int J Epidemiol*. 2019;48:926-933. doi:10.1093/ije/dyz002
11. Carstens C, Linley J. Desire to quit smoking in an outpatient population of persons with serious mental illness. *J Behav Health Serv Res*. 2020;47:560-568. doi:10.1007/s11414-020-09698-1
12. Cheezum MK, Kim A, Bittencourt MS, et al. Association of tobacco use and cessation with coronary atherosclerosis. *Atherosclerosis*. 2017;257:201-207. doi:10.1016/j.atherosclerosis.2016.11.016
13. Chou SP, Goldstein RB, Smith SM, et al. The epidemiology of DSM-5 nicotine use disorder: results from the National Epidemiologic Survey on alcohol and related conditions-III. *J Clin Psychiatry*. 2016;77:1404-1412. doi:10.4088/JCP.15m10114
14. Chou SP, Lee HK, Cho MJ, Park J-I, Dawson DA, Grant BF. Alcohol use disorders, nicotine dependence, and Co-occurring mood and anxiety disorders in the United States and South Korea—a cross-National Comparison. *Alcohol Clin Exp Res*. 2012;36:654-662. doi:10.1111/j.1530-0277.2011.01639.x
15. Davy V, Brendon S, Mitchell AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. *World Psychiatry*. 2015;14:339-347. doi:10.1002/wps.20252
16. DeBry SC, Tiffany ST. Tobacco-induced neurotoxicity of adolescent cognitive development (TINACD): a proposed model for the development of impulsivity in nicotine dependence. *Nicotine Tob Res*. 2008;10:11-25. doi:10.1080/14622200701767811
17. Ducasse D, Jausent I, Guillaume S, et al. Increased risk of suicide attempt in bipolar patients with severe tobacco dependence. *J Affect Disord*. 2015;183:113-118. doi:10.1016/j.jad.2015.04.038
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). *JAMA*. 2001;285:2486-2497. doi:10.1001/jama.285.19.2486
19. First MB, Gibbon M, Spitzer RL, William JB, Benjamin LS. *Structured Clinical Interview for DSM-IV® Axis I Personality Disorders SCID-II*. American Psychiatric Pub; 1997.
20. Firth J, Solmi M, Wootton RE, et al. A meta-review of “lifestyle psychiatry”: the role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders. *World Psychiatry*. 2020;19:360-380. doi:10.1002/wps.20773
21. Gilbody S, Peckham E, Bailey D, et al. Smoking cessation for people with severe mental illness (SCIMITAR+): a pragmatic randomised controlled trial. *Lancet Psychiatry*. 2019;6:379-390. doi:10.1016/S2215-0366(19)30047-1
22. Gonseth S, Jacot-Sadowski I, Diethelm PA, Barras V, Cornuz J. The tobacco industry's past role in weight control related to smoking. *Eur J Public Health*. 2012;22:234-237. doi:10.1093/eurpub/ckr023
23. Hacimusalar Y, Karaaslan O, Misir E, Amuk OC, Hacimusalar G. Sleep quality impairments in schizophrenia and bipolar affective disorder patients continue during periods of remission: a case-controlled study. *Sleep Sci*. 2022;15:47-54. doi:10.5935/1984-0063.20210036
24. Harvey PD, Greenberg BR, Serper MR. The affective lability scales: development, reliability, and validity. *J Clin Psychol*. 1989;45:786-793. doi:10.1002/1097-4679(198909)45:53.0.CO;2-P
25. Heffner JL, DelBello MP, Fleck DE, Anthenelli RM, Strakowski SM. Cigarette smoking in the early course of bipolar disorder: association with ages-at-onset of alcohol and marijuana use. *Bipolar Disord*. 2008;10:838-845. doi:10.1111/j.1399-5618.2008.00630.x
26. Heffner JL, Evins AE, Russ C, et al. Safety and efficacy of first-line smoking cessation pharmacotherapies in bipolar disorders: subgroup analysis of a randomized clinical trial. *J Affect Disord*. 2019;256:267-277. doi:10.1016/j.jad.2019.06.008
27. Heffner JL, Fleck DE, DelBello MP, Adler CM, Strakowski SM. Cigarette smoking and impulsivity in bipolar disorder. *Bipolar Disord*. 2012;14:735-742. doi:10.1111/bdi.12010
28. Heffner JL, Kelly MM, Waxmonsky J, et al. Pilot randomized controlled trial of web-delivered acceptance and commitment therapy versus Smokefree.gov for smokers with bipolar disorder. *Nicotine Tob Res*. 2020;22:1543-1552. doi:10.1093/ntr/ntz242
29. Henry C, Etain B, Godin O, et al. Bipolar patients referred to specialized services of care: not resistant but impaired by sub-syndromal symptoms. Results from the FACE-BD cohort. *Aust N Z J Psychiatry*. 2015;49:898-905. doi:10.1177/0004867415585582
30. Henry C, Etain B, Mathieu F, et al. A French network of bipolar expert centres: a model to close the gap between evidence-based medicine and routine practice. *J Affect Disord*. 2011;131:358-363. doi:10.1016/j.jad.2010.11.013
31. Henry C, Godin O, Courtet P, et al. Outcomes for bipolar patients assessed in the French expert center network: a 2-year follow-up observational study (FondaMental advanced Centers of expertise for bipolar disorder [FACE-BD]). *Bipolar Disord*. 2017;19:651-660. doi:10.1111/bdi.12539
32. Icick R, Gard S, Barde M, et al. Physical and mental health burden in cases of bipolar disorder classified as current, former, or non-tobacco smokers. *J Affect Disord*. 2017;208:406-413. doi:10.1016/j.jad.2016.09.022
33. Icick R, Gard S, M'Bailara K, et al. The course of bipolar disorder as a function of the presence and sequence of onset of comorbid alcohol use disorders in outpatients attending the Fondamental advanced Centres of expertise. *J Affect Disord*. 2021;287:196-203. doi:10.1016/j.jad.2021.03.041
34. Icick R, Melle I, Etain B, et al. Preventive medication patterns in bipolar disorder and their relationship with comorbid substance use disorders in a cross-National Observational Study. *Front Psych*. 2022;13:813256. doi:10.3389/fpsy.2022.813256
35. Icick R, Melle I, Etain B, et al. Tobacco smoking and other substance use disorders associated with recurrent suicide attempts in bipolar disorder. *J Affect Disord*. 2019;256:348-357. doi:10.1016/j.jad.2019.05.075
36. Kertes J, Neumark Y, Grunhaus L, Stein-Reisner O. Comparison of perceptions and smoking cessation experiences between smokers with and without serious mental illness in a large health maintenance organization. *J Dual Diagn*. 2021;17:284-295. doi:10.1080/15504263.2021.1979348
37. Kessing LV, Ziersen SC, Andersen PK, Vinberg M. A nationwide population-based longitudinal study on life expectancy and cause specific mortality in patients with bipolar disorder and their siblings. *J Affect Disord*. 2021;294:472-476. doi:10.1016/j.jad.2021.07.065



38. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study. *Jama*. 2000;284:2606-2610. doi:10.1001/jama.284.20.2606
39. Leboyer M, Godin O, Llorca PM, et al. Key findings on bipolar disorders from the longitudinal FondaMental Advanced Center of Expertise-Bipolar Disorder (FACE-BD) cohort. *J Affect Disord*. 2022;307:149-156. doi:10.1016/j.jad.2022.03.053
40. Li MD, Parker SL, Kane JK. Regulation of feeding-associated peptides and receptors by nicotine. *MN*. 2000;22:143-166. doi:10.1385/MN:22:1-3:143
41. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. *Br J Psychiatry*. 1979;134:382-389. doi:10.1192/bjpp.134.4.382
42. Nielsen RE, Banner J, Jensen SE. Cardiovascular disease in patients with severe mental illness. *Nat Rev Cardiol*. 2021;18:136-145. doi:10.1038/s41569-020-00463-7
43. Nobile B, Dubois J, Aouizerate B, et al. Characterization of depressed bipolar patients with current suicidal ideation. *Aust New Zealand J Psychiatry*. 2020;55:289-304. doi:10.1177/0004867420963744
44. Ostacher MJ, LeBeau RT, Perlis RH, et al. Cigarette smoking is associated with suicidality in bipolar disorder. *Bipolar Disord*. 2009;11:766-771. doi:10.1111/j.1399-5618.2009.00744.x
45. Paquette D, Laporte L, Bigras M, Zoccolillo M. Validation of the French version of the CTQ and prevalence of the history of maltreatment. *Sante Ment Que*. 2004;29:201-220.
46. Peckham E, Brabyn S, Cook L, Tew G, Gilbody S. Smoking cessation in severe mental ill health: what works? An updated systematic review and meta-analysis. *BMC Psychiatry*. 2017;17:252. doi:10.1186/s12888-017-1419-7
47. Prochaska JJ, Reyes RS, Schroeder SA, Daniels AS, Doederlein A, Bergeson B. An online survey of tobacco use, intentions to quit, and cessation strategies among people living with bipolar disorder. *Bipolar Disord*. 2011;13:466-473. doi:10.1111/j.1399-5618.2011.00944.x
48. Rosa AR, Sánchez-Moreno J, Martínez-Aran A, et al. Validity and reliability of the functioning assessment short test (FAST) in bipolar disorder. *Clin Pract Epidemiol Ment Health*. 2007;3:5. doi:10.1186/1745-0179-3-5
49. Scherf-Clavel M, Deckert J, Menke A, Unterecker S. Smoking is associated with lower dose-corrected serum concentrations of escitalopram. *J Clin Psychopharmacol*. 2019;39:485-488. doi:10.1097/JCP.0000000000001080
50. Slomka JM, Piette JD, Post EP, et al. Mood disorder symptoms and elevated cardiovascular disease risk in patients with bipolar disorder. *J Affect Disord*. 2012;138:405-408. doi:10.1016/j.jad.2012.01.005
51. Steffens EB, Park ER, Muzikansky A, et al. Patients with serious mental illness can engage in tobacco treatment trials and tobacco cessation interventions during cancer treatment. *JCO Oncol Pract*. 2022;19:OP.22.00505. doi:10.1200/OP.22.00505
52. Taylor G, McNeill A, Girling A, Farley A, Lindson-Hawley N, Aveyard P. Change in mental health after smoking cessation: systematic review and meta-analysis. *BMJ*. 2014;348:g1151. doi:10.1136/bmj.g1151
53. Tsopelas C, Kardaras K, Kontaxakis V. Smoking in patients with psychiatric disorders: effects on their psychopathology and quality of life. *Psychiatriki*. 2008;19:306-312.
54. Vancampfort D, Correll CU, Galling B, et al. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. *World Psychiatry*. 2016;15:166-174. doi:10.1002/wps.20309
55. Vermeulen JM, van Rooijen G, van de Kerkhof MPJ, Sutherland AL, Correll CU, de Haan L. Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1–12.5 years. *Schizophr Bull*. 2019;45:315-329. doi:10.1093/schbul/sby052
56. Vestergaard JH, Sivapalan P, Sørensen R, et al. Depressive symptoms among patients with COPD according to smoking status: a Danish nationwide case-control study of 21 184 patients. *ERJ Open Res*. 2020;6:2020. doi:10.1183/23120541.00036-2020
57. Waxmonsky JA, Thomas MR, Miklowitz DJ, et al. Prevalence and correlates of tobacco use in bipolar disorder: data from the first 2000 participants in the systematic treatment enhancement program. *Gen Hosp Psychiatry*. 2005;27:321-328. doi:10.1016/j.genhosppsych.2005.05.003
58. Williams JM, Gandhi KK, Lu S-E, Steinberg ML, Benowitz NL. Nicotine intake and smoking topography in smokers with bipolar disorder: nicotine intake and smoking topography. *Bipolar Disord*. 2012;14:618-627. doi:10.1111/j.1399-5618.2012.01047.x
59. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. *Br J Psychiatry*. 1978;133:429-435. doi:10.1192/bjp.133.5.429

**How to cite this article:** Nobile B, Godin O, Gard S, et al. Physical and mental health status of former smokers and non-smokers patients with bipolar disorder. *Acta Psychiatr Scand*. 2023;147(4): 373-388. doi:10.1111/acps.13535